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(2005) from initial scoping to ﬁnal appraisal determination,
comparing observations with process deﬁnitions by NICE and
with published evidence. RESULTS: The overall process strictly
adhered to NICE standards in terms of stakeholder participa-
tion, predictability, and timelines. The technology assessment
revealed a marked gap between clinical effectiveness review (cov-
ering improvements in hyperactivity, including 64 randomized
studies) and data selected for economic modeling (ﬁve short-term
studies, plus one previously excluded for quality concerns),
resulting from an imposed restriction to trials reporting CGI-I
scores, which were used to estimate utility weights for QALY cal-
culations—while existing cost-effectiveness data were discarded.
Also secondary extensions of the model (comprising 14 trials)
excluded most published long-term studies. Quantitative data
synthesis did not reﬂect heterogeneity between observational and
randomized controlled studies, thus eliminating any potential
impact of differences in treatment adherence, while comparing
drugs with different administration schedules. Further technical
problems were identiﬁed with the assessment report. In combi-
nation, these problems led to untenable conclusions. Only part
of these problems was remedied during the subsequent appraisal
process. CONCLUSIONS: Implications exceed the issue of clin-
ical evidence required for treatment differentiation. Highly stan-
dardized approaches like that adopted by NICE, exclusively
considering cost-utility analyses, characterized by a separation of
economic analysis and clinical evaluation (including, but not
limited to, guideline development) and absence of effective
quality management of technology assessments may result in
suboptimal, potentially misleading technology appraisals.
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OBJECTIVES: Long-acting risperidone injectable (LARI) is
available for patients with schizophrenia, as advance to depot
antipsychotic agents. This work aims to review the literature arti-
cles of health outcomes between 1995 and 2005 relating to
deport antipsychotic agents and LARI. METHODS: Two data-
bases Ovid Medline and EMBase were used in December 2005
to extract the articles with a focus on health outcomes including
effectiveness on compliance/adherence, efﬁcacy and effectiveness
on improving psychiatric symptoms and quality of life, health
care utilization and cost, cost-effectiveness, dosing information,
and treatment patterns of depot antipsychotic agents and LARI.
Key words “depot antipsychotics”, “delayed-action prepara-
tions”, “long-acting” and “schizophrenia” were used in the
search to extract a total of 219 full text articles including previ-
ous review articles during the period. RESULTS: While depot
antipsychotic agents were shown to be efﬁcacious in improving
symptoms and quality of life, and to be well tolerated, the 
information is limited to show its effectiveness on improving
adherence and reducing health care utilization and costs. The
treatment and dosing patterns of depot antipsychotic agents were
confounded by socio-demographic factors and treatment set-
tings. Generally favourable views on depot antipsychotic agents
existed for patients, psychiatrists and nurses. Between 1995 and
2005, there were 5 published cost-effectiveness models in the
United States (2), UK (1), France (1), and Taiwan (1) showing
treatment cost saving associated with depot antipsychotics and
LARI. Additionally, only 4 depot treatment guidelines including
one speciﬁcally for dosing and switching and another one for the
use of depot in elderly existed in the literature. CONCLUSION:
Depot antipsychotic agents and LARI need to be studied in high-
quality effectiveness research in patients with schizophrenia, who
have problems with treatment adherence, in order to develop evi-
dence-based treatment/rehabilitation alliance for patients, family
members, psychiatrists, and nurses.
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OBJECTIVES: The study assessed the impact of using off-label
mood stabilizers on total health expenditures, inpatient hospi-
talizations, long term care stays and emergency room (ER) visits
for patients with schizophrenia. METHODS: Georgia Medicaid
claims from 1999–2001 were analyzed for schizophrenic patients
≥16 years who initiated antipsychotic or mood stabilizer treat-
ment between April 1999 and December 2000. A mood stabi-
lizer was considered off-label if none of the ICD-9-CM codes
could be matched with the labeled indications. The treatment
group was formed of subjects who received an off-label mood
stabilizer within 14 days after the treatment initiation, while the
comparison group consisted of subjects who did not have any
exposure to off-label mood stabilizers during the study period.
Differences in annual outcomes were estimated between propen-
sity score matched off-label and on-label users. RESULTS: A
total of 830 pairs off-label and on-label users were successfully
matched. During the one year observation period, both groups
shared a similar antipsychotic utilization pattern and the off-
label group ﬁlled an average 170.32 ± 117.69 days supply of
mood stabilizers. The off-label group experienced signiﬁcantly
higher total health costs (net difference: $2060.52; P < 0.0001)
than the on-label group. The difference was mainly driven by the
higher drug cost (net difference: $907.09; P < 0.0001) and long
term care cost (net difference: $572.50; P = 0.0645) associated
with the off-label users. Excess utilization of general and mental
health related hospital, long term care and ER services were also
observed in the off-label group; however, none of these differ-
ences was statistically signiﬁcant. CONCLUSIONS: Use of 
off-label mood stabilizer may increase total health cost without
reducing the utilization of hospital, long term care stays and ER
services. Despite the widespread off-label use of mood stabilizer,
the result of this study does not support the long term utiliza-
tion of off-label mood stabilizers among schizophrenic patients.
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OBJECTIVES: This analysis examined the impact of demo-
graphic, clinical characteristic, and health care resource utiliza-
tion variables on the choice of three atypical antipsychotics
(olanzapine, risperidone, quetiapine) used to treat bipolar disor-
der. METHODS: Sample is drawn from the North Carolina
Medicaid claims database between November 1, 2000 and
November 1, 2003. To be included in this analysis, patients had
to have three months continuous enrollment prior to initiating
monotherapy with olanzapine, risperidone or quetiapine.
Patients had to be 18 to 64 years of age, with no atypical antipsy-
chotic treatment or bipolar diagnosis during the three months
